Skip to main content
Premium Trial:

Request an Annual Quote

Symyx Board Again Rejects Certara Bid

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Symyx Technologies said last night after the close of the market that its board of directors has once again rejected Certara's bid to acquire the firm for $5.75 per share, or around $200 million, saying that it does not constitute a superior offer to Accelrys' bid to acquire the company.

This is the second time this week that the Symyx board has rejected the Certara offer, which is higher than Acclerys' $5 per share bid. The Symyx board has stated that a combination with Accelrys offers a greater upside and has urged Symyx shareholders to support the Accelrys bid.

San Diego-based Accelrys issued a separate release last night saying that independent proxy advisory firm Institutional Shareholder Services has recommended Accelrys' shareholders vote in favor of the merger with Symyx next week.

Under the deal, shareholders of each firm would own roughly half of the combined life science informatics company. The firms expect full-year net synergies of between $10 million and $15 million, and annualized revenues of more than $160 million.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.